Department of Radiation Medicine, Northwell Health, Lake Success, New York; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
Department of Physics and Engineering Physics, Fordham University, Bronx, New York.
Pract Radiat Oncol. 2019 Mar;9(2):e228-e235. doi: 10.1016/j.prro.2018.10.016. Epub 2018 Nov 8.
Peer review is an essential component of quality assurance programs in radiation oncology. The purpose of this work was to assess whether peer reviewers recommend expansion or reduction of planning target volumes (PTVs) and organs at risk (OARs) in prospective multidisciplinary daily contour rounds.
The peer group evaluated the appropriateness of PTVs and OARs for each case according to evidence-based departmental directives. We reviewed 7645 cases that presented between September 2013 and March 2017. We isolated recommendations for PTV/OAR modification and classified each as expansion, reduction, both, or indeterminate. Recommendations were analyzed by technique, site, and physician experience.
Eight junior and 7 senior radiation oncologists were included. PTV or OAR modifications were recommended for 750 of 7645 prescriptions (9.7%). The peer group recommended PTV modifications for 534 prescriptions (7.0%): There were 309 expansions (57.9%), 115 reductions (21.5%), 15 both (2.8%), and 95 indeterminate (17.8%). Reasons for PTV expansions included increased nodal coverage and inadequate margins as a result of motion. The peer group recommended OAR modifications for 216 prescriptions (2.8%): There were 102 expansions (47.2%), 23 reductions (10.6%), 2 both (0.9%), and 89 indeterminate (41.2%). Reasons for OAR expansions included missing critical structures and inadequate extent as per departmental standardization. Head and neck represented the largest percentage of PTV recommendations (28.8%). Intensity modulated radiation therapy plans received the most PTV and OAR recommendations (66.8% and 74.5%, respectively). The recommendation rate for senior and junior faculty was 43% and 28%, respectively.
Peer review resulted in recommendations for PTV or OAR change for approximately 10% of cases. Expansions of PTV were recommended >2.5 times more often than reductions and >3 times more often than OAR expansions. This general trend was identified for treatment technique, site, and physician experience. Prospective peer review could yield systematically larger volumes, which could affect multicenter clinical trials.
同行评议是放射肿瘤学质量保证计划的重要组成部分。本研究旨在评估在多学科每日靶区勾画前瞻性审查中,同行评审员是否建议扩大或缩小计划靶区(PTV)和危及器官(OAR)。
根据循证科室指南,同行评审组对每个病例的 PTV 和 OAR 的适宜性进行评估。我们回顾了 2013 年 9 月至 2017 年 3 月期间的 7645 例病例。我们将靶区和危及器官的修改建议分类为扩大、缩小、同时或不确定。并根据技术、部位和医生经验对建议进行分析。
共纳入 8 名初级和 7 名高级放疗医师。7645 例处方中,有 750 例(9.7%)建议修改 PTV/OAR。同行评审组建议修改 PTV 处方 534 例(7.0%):其中 309 例扩大(57.9%),115 例缩小(21.5%),15 例同时(2.8%),95 例不确定(17.8%)。扩大 PTV 的原因包括因运动导致的淋巴结覆盖增加和边缘不足。同行评审组建议修改 OAR 处方 216 例(2.8%):其中 102 例扩大(47.2%),23 例缩小(10.6%),2 例同时(0.9%),89 例不确定(41.2%)。OAR 扩大的原因包括遗漏关键结构和不满足科室规范化要求的范围。头颈部占 PTV 建议的最大比例(28.8%)。调强放疗计划接受了最多的 PTV 和 OAR 建议(分别为 66.8%和 74.5%)。高级和初级教员的建议率分别为 43%和 28%。
同行评审导致约 10%的病例建议修改 PTV 或 OAR。与缩小相比,PTV 扩大的建议多 2.5 倍以上,与 OAR 扩大的建议多 3 倍以上。这种总体趋势在治疗技术、部位和医生经验中都得到了体现。前瞻性同行评审可能会产生系统上更大的靶区体积,这可能会影响多中心临床试验。